We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 12, 2019

Intravenous NEPA for Prevention of CINV in Patients With Breast Cancer Receiving AC Chemotherapy

The Oncologist


Additional Info

The Oncologist
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
Oncologist 2019 Dec 04;[EPub Ahead of Print], L Schwartzberg, R Navari, R Clark-Snow, E Arkania, I Radyukova, K Patel, D Voisin, G Rizzi, R Wickham, RJ Gralla, M Aapro, E Roeland

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading